<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX35" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES" code="P01B-001" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, domperidone, escitalopram, hydroxyzine, and piperaquin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="AZITHROMYCIN " rxcui="18631">
<ATC code="J01FA10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="BRADYCARDIA INDUCING DRUGS" code="C0N0S0" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="CIPROFLOXACIN" rxcui="2551">
<ATC code="J01MA02" />
<ATC code="S01AE03" />
<ATC code="S02AA15" />
<ATC code="S03AA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
<ATC code="A02BD04" />
<ATC code="A02BD05" />
<ATC code="A02BD06" />
<ATC code="A02BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="HYDROXYCHLOROQUINE" rxcui="5521">
<ATC code="P01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Correct all hypokaliemia before administering the product and do clinical and electrolyte monitoring and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="LEVOFLOXACIN" rxcui="82122">
<ATC code="J01MA12" />
<ATC code="S01AE05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES" code="N05A-002" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="NORFLOXACIN" rxcui="7517">
<ATC code="J01MA06" />
<ATC code="S01AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="ONDANSETRON" rxcui="26225">
<ATC code="A04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>484-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG1>
<DRUG2>
<CLASS name="TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)" code="C01B" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>--For dolasetron, erythromycin, spiramycin and vicamine, only the forms administerd by IV route are concerned by this interaction</COMMENT>
</INTERACTION>
</INTERACTIONS>
